Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

N Engl J Med. 2020 Jan 2;382(1):92. doi: 10.1056/NEJMc1915739.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal, Humanized
  • Colitis, Ulcerative*
  • Humans
  • Infliximab

Substances

  • Antibodies, Monoclonal, Humanized
  • vedolizumab
  • Infliximab
  • Adalimumab